Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4 - PubMed (original) (raw)
. 2003 Jul 11;278(28):26258-64.
doi: 10.1074/jbc.M301484200. Epub 2003 Apr 30.
Affiliations
- PMID: 12724322
- DOI: 10.1074/jbc.M301484200
Free article
Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4
Caroline A Jefferies et al. J Biol Chem. 2003.
Free article
Abstract
In this study we have identified members of the Toll-like receptor (TLR) family (namely, TLRs 4, 6, 8, and 9) as proteins to which the intracellular protein tyrosine kinase, Bruton's tyrosine kinase (Btk), binds. Detailed analysis of the interaction between Btk and TLR8 demonstrates that the presence of both Box 2 and 3 motifs in the Toll/interleukin-1 receptor domain was required for the interaction. Furthermore, co-immunoprecipitation experiments revealed that Btk can also interact with key proteins involved in TLR4 signal transduction, namely, MyD88, Mal (MyD88 adapter-like protein), and interleukin-1 receptor-associated kinase-1, but not TRAF-6. The ability of Btk to interact with TLR4 and Mal suggests a role for Btk in lipopolysaccharide (LPS) signal transduction. Stimulation of the human monocytic cell line THP-1 with LPS resulted in an increase in the level of tyrosine phosphorylation of Btk (indicative of activation). The autokinase activity of Btk was also stimulated after LPS stimulation. In addition, a dominant negative form of Btk inhibited TLR4-mediated activation of a nuclear factor kappaB (NFkappaB)-dependent reporter gene in HEK293 cells as well as LPS-induced activation of NFkappaB in the astrocytoma cell line U373 and the monocytic cell line RAW264.7. Further investigation revealed that the Btk-specific inhibitor, LFM-A13, inhibited the activation of NFkappaB by LPS in THP-1 cells. Our findings implicate Btk as a Toll/interleukin-1 receptor domain-binding protein that is important for NFkappaB activation by TLR4.
Similar articles
- MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction.
Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA. Gray P, et al. J Biol Chem. 2006 Apr 14;281(15):10489-95. doi: 10.1074/jbc.M508892200. Epub 2006 Jan 26. J Biol Chem. 2006. PMID: 16439361 - Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide.
Doyle SL, Jefferies CA, O'Neill LA. Doyle SL, et al. J Biol Chem. 2005 Jun 24;280(25):23496-501. doi: 10.1074/jbc.C500053200. Epub 2005 Apr 22. J Biol Chem. 2005. PMID: 15849198 - Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling?
Jefferies CA, O'Neill LA. Jefferies CA, et al. Immunol Lett. 2004 Mar 29;92(1-2):15-22. doi: 10.1016/j.imlet.2003.11.017. Immunol Lett. 2004. PMID: 15081522 Review. - Phosphoinositide 3 kinase mediates Toll-like receptor 4-induced activation of NF-kappa B in endothelial cells.
Li X, Tupper JC, Bannerman DD, Winn RK, Rhodes CJ, Harlan JM. Li X, et al. Infect Immun. 2003 Aug;71(8):4414-20. doi: 10.1128/IAI.71.8.4414-4420.2003. Infect Immun. 2003. PMID: 12874320 Free PMC article. - IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW. Parrondo RD, et al. Front Immunol. 2023 Oct 26;14:1239082. doi: 10.3389/fimmu.2023.1239082. eCollection 2023. Front Immunol. 2023. PMID: 37954584 Free PMC article. Review.
Cited by
- Relationship between Glutathione-Dependent Enzymes and the Immunohistochemical Profile of Glial Neoplasms.
Obukhova L, Kopytova T, Murach E, Shchelchkova N, Kontorshchikova C, Medyanik I, Orlinskaya N, Grishin A, Kontorshchikov M, Badanina D. Obukhova L, et al. Biomedicines. 2022 Sep 25;10(10):2393. doi: 10.3390/biomedicines10102393. Biomedicines. 2022. PMID: 36289655 Free PMC article. - Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Geladaris A, Torke S, Weber MS. Geladaris A, et al. CNS Drugs. 2022 Oct;36(10):1019-1030. doi: 10.1007/s40263-022-00951-z. Epub 2022 Sep 30. CNS Drugs. 2022. PMID: 36178589 Free PMC article. Review. - Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling.
Ryu KY, Lee HJ, Woo H, Kang RJ, Han KM, Park H, Lee SM, Lee JY, Jeong YJ, Nam HW, Nam Y, Hoe HS. Ryu KY, et al. J Neuroinflammation. 2019 Oct 26;16(1):190. doi: 10.1186/s12974-019-1561-x. J Neuroinflammation. 2019. PMID: 31655606 Free PMC article. - Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies.
Cao X, Jin X, Zhang X, Utsav P, Zhang Y, Guo R, Lu W, Zhao M. Cao X, et al. Curr Treat Options Oncol. 2023 Mar;24(3):184-211. doi: 10.1007/s11864-023-01049-4. Epub 2023 Jan 26. Curr Treat Options Oncol. 2023. PMID: 36701037 Free PMC article. Review. - Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3.
Kawakami Y, Inagaki N, Salek-Ardakani S, Kitaura J, Tanaka H, Nagao K, Kawakami Y, Xiao W, Nagai H, Croft M, Kawakami T. Kawakami Y, et al. Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):153-8. doi: 10.1073/pnas.0509784103. Epub 2005 Dec 21. Proc Natl Acad Sci U S A. 2006. PMID: 16371463 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous